Opendata, web and dolomites

VANGUARD SIGNED

New Generation Cell Therapy: Bioartificial Pancreas to Cure Type 1 Diabetes

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 VANGUARD project word cloud

Explore the words cloud of the VANGUARD project. It provides you a very rough idea of what is the project "VANGUARD" about.

immunomodulatory    inflammatory    graft    transplantation    beta    delivered    therapy    academic    destruction    million    pancreas    overexpress    utilizing    cells    revascularization    disease    translational    worldwide    limited    suffer    atmp    extracellular    forty    majority    scientists    rapid    locally    insulin    devastating    managed    implantation    construct    hla    amniotic    replacement    implantability    ngo    patients    sources    pd    confer    accessibility    anti    smes    matrix    human    chronic    protection    haec    ethical    cell    producing    clinical    hydrogel    therapies    urgent    vivo    consists    social    vast    larger    constructs    vanguard    stem    blood    release    membrane    edited    therapeutic    genome    haecs    vitro    assembling    cd47    boecs    complications    organoids    bioartificial    islet    expertise    biocompatibility    endothelial    completion    xenogeneic    molecules    l1    components    safety    model    mice    immune    reconstituted    diabetes    diabetic    epithelial    langerhans    medicinal    mechanical    potency    infinite    outgrowth    individuals   

Project "VANGUARD" data sheet

The following table provides information about the project.

Coordinator
UNIVERSITE DE GENEVE 

Organization address
address: RUE DU GENERAL DUFOUR 24
city: GENEVE
postcode: 1211
website: www.unige.ch

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Switzerland [CH]
 Total cost 6˙844˙625 €
 EC max contribution 6˙844˙625 € (100%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SC1-2019-Single-Stage-RTD
 Funding Scheme RIA
 Starting year 2020
 Duration (year-month-day) from 2020-01-01   to  2024-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    UNIVERSITE DE GENEVE CH (GENEVE) coordinator 1˙995˙946.00
2    OSPEDALE SAN RAFFAELE SRL IT (MILANO) participant 1˙049˙500.00
3    UNIVERSITA DEGLI STUDI DEL PIEMONTE ORIENTALE AMEDEO AVOGADRO IT (VERCELLI) participant 936˙875.00
4    LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN DE (MUENCHEN) participant 804˙375.00
5    KUGELMEIERS AG CH (ERLENBACH) participant 701˙250.00
6    UNIVERSITE LYON 1 CLAUDE BERNARD FR (VILLEURBANNE CEDEX) participant 523˙812.00
7    ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM NL (ROTTERDAM) participant 393˙116.00
8    ACCELOPMENT AG CH (ZUERICH) participant 384˙750.00
9    EUROPEAN SOCIETY FOR ORGAN TRANSPLANTATION NL (AMSTERDAM) participant 55˙000.00

Map

 Project objective

Forty million individuals worldwide suffer from type 1 diabetes. This disease is managed by insulin therapy in a vast majority of patients because of the limited accessibility of beta cell replacement therapies (pancreas or islet of Langerhans transplantation). There is an urgent need for the development of a beta cell replacement therapy that will be available to larger numbers of type 1 diabetic patients. The VANGUARD project aims to deliver an Advanced Therapeutic Medicinal Product (ATMP) of high translational potential, with properties of increased functionality and implantability and protection from immune destruction. We will construct a bioartificial pancreas by assembling insulin- producing organoids, composed of islet cells, human amniotic epithelial cells (hAEC) and blood outgrowth endothelial cells (BOECs), into an amniotic membrane-derived hydrogel. Components of the amniotic membrane will provide extracellular matrix and mechanical protection and confer their well-defined anti-inflammatory and immunomodulatory properties to the constructs. hAECs will be genome-edited to overexpress and locally release immunomodulatory molecules (HLA-G, HLA-E, CD47 and PD-L1) and endothelial cells will enhance graft revascularization. Functionality, biocompatibility, potency and safety of the bioartificial pancreas will be assessed in vitro and in vivo by implantation in mice reconstituted with a human immune system as pre-clinical model. The consortium consists of 5 academic institutions with leading scientists in their field, 2 SMEs and 1 NGO with expertise in ethical and social aspects of transplantation. The ATMP delivered upon completion of the project will provide a model for rapid development of a bioartificial pancreas, utilizing “infinite” sources of insulin-producing cells (stem cell-derived, xenogeneic), and available to all type 1 diabetic patients before they develop the devastating chronic complications of the disease.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "VANGUARD" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "VANGUARD" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

PREFERABLE (2019)

Project on Exercise for Fatigue Eradication in Advanced Breast cancer to improve quality of life

Read More  

ESCALON (2019)

European-Latin American network for the assessment of biomarkers to predict and diagnose hepatobiliary malignancies and characterization of risk factors for cancer development

Read More  

GACD (2019)

Global Alliance for Chronic Diseases Secretariat

Read More